enVVeno Medical Corporation

NasdaqCM NVNO

enVVeno Medical Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

enVVeno Medical Corporation EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

enVVeno Medical Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -37,616.54%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: NVNO

enVVeno Medical Corporation

CEO	Mr. Robert A. Berman
IPO Date	May 31, 2018
Location	United States
Headquarters	70 Doppler
Employees	31
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Eyewear Fintech Glass Medical Instruments Pharmaceuticals

Description

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Key trends

Past 5 years